EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Ryan B Rush iD

Clinical Ophthalmology · 2023-08 · Volume 17 · 2201-2208

DOI: 10.2147/opth.s424315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ophthalmology, 2023-08. Verfasst von Ryan B Rush. Beteiligte Einrichtung: Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

faricimabneovascular age-related macular degenerationrecalcitrancetreatment-resistant

Autor:innen und Institutionen

  • Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA.
  • Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX, USA.
  • Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA.

ORCID-Profile: Ryan B Rush

Zitieren

APA

Rush, R. B. (2023). One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, Volume 17, 2201-2208. https://doi.org/10.2147/opth.s424315

Vancouver

Rush RB. One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology. 2023;Volume 17:2201-2208. doi:10.2147/opth.s424315

BibTeX
@article{Rush2023,
  author = {Rush, Ryan B},
  title = {One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration},
  journal = {Clinical Ophthalmology},
  year = {2023},
  volume = {Volume 17},
  pages = {2201--2208},
  doi = {10.2147/opth.s424315}
}
Kostenlos starten →